AR and Familial prostate cancer: Interestingly, in the same study, they were able to show inhibition of the proliferation of the androgen-independent 22Rv1 cell line, suggesting that HDAC-3-specific inhibitor treatment could be very useful for treating castration-resistant prostate cancers (CRPCs), in which the constitutively active androgen receptor (AR) splice variant AR-V7 is expressed and dominant over wtAR [41].